1. Home
  2. RAMP vs IMNM Comparison

RAMP vs IMNM Comparison

Compare RAMP & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LiveRamp Holdings Inc.

RAMP

LiveRamp Holdings Inc.

HOLD

Current Price

$37.52

Market Cap

2.3B

Sector

Technology

ML Signal

HOLD

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$21.56

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RAMP
IMNM
Founded
2018
2006
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.5B
IPO Year
1994
2020

Fundamental Metrics

Financial Performance
Metric
RAMP
IMNM
Price
$37.52
$21.56
Analyst Decision
Buy
Strong Buy
Analyst Count
5
10
Target Price
★ $35.60
$32.80
AVG Volume (30 Days)
★ 1.1M
975.9K
Earning Date
05-20-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 22500.00
51.40
EPS
★ 0.28
N/A
Revenue
★ $812,940,000.00
$6,941,000.00
Revenue This Year
$11.18
N/A
Revenue Next Year
$9.09
$1,127.34
P/E Ratio
$133.86
★ N/A
Revenue Growth
★ 9.03
N/A
52 Week Low
$21.71
$11.09
52 Week High
$38.23
$30.06

Technical Indicators

Market Signals
Indicator
RAMP
IMNM
Relative Strength Index (RSI) 43.09 31.93
Support Level $37.29 $19.39
Resistance Level $37.92 $23.25
Average True Range (ATR) 0.16 1.19
MACD -0.03 -0.40
Stochastic Oscillator 13.16 5.33

Price Performance

Historical Comparison
RAMP
IMNM

About RAMP LiveRamp Holdings Inc.

LiveRamp Holdings Inc is a technology company that empowers marketers and media owners to deliver and measure marketing performance everywhere it matters. Its data collaboration network seamlessly unites data across advertisers, ad tech platforms, publishers, data providers, and commerce media networks, unlocking insights that deliver transformational consumer experiences and drive measurable business outcomes. The group's platform is engineered for AI agent accessibility, facilitating autonomous data collaboration between the specialized AI agents utilized by customers and partners and the networked platform. It generates the geographic revenue from the United States, followed by Europe, Asia-Pacific ("APAC"), and Other.

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

Share on Social Networks: